These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Fowler RA; Sanders GD; Bravata DM; Nouri B; Gastwirth JM; Peterson D; Broker AG; Garber AM; Owens DK Ann Intern Med; 2005 Apr; 142(8):601-10. PubMed ID: 15838066 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity. Kyriacou DN; Dobrez D; Parada JP; Steinberg JM; Kahn A; Bennett CL; Schmitt BP Biosecur Bioterror; 2012 Sep; 10(3):264-79. PubMed ID: 22845046 [TBL] [Abstract][Full Text] [Related]
5. Modeling Tool for Decision Support during Early Days of an Anthrax Event. Rainisch G; Meltzer MI; Shadomy S; Bower WA; Hupert N Emerg Infect Dis; 2017 Jan; 23(1):46-55. PubMed ID: 27983505 [TBL] [Abstract][Full Text] [Related]
6. Re-assessment of mitigation strategies for deliberate releases of anthrax using a real-time outbreak characterization tool. Egan JR; Legrand J; Hall IM; Cauchemez S; Ferguson NM; Leach S Epidemics; 2010 Dec; 2(4):189-94. PubMed ID: 21352789 [TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of strategies to reduce mortality from an intentional release of aerosolized anthrax spores. Braithwaite RS; Fridsma D; Roberts MS Med Decis Making; 2006; 26(2):182-93. PubMed ID: 16525172 [TBL] [Abstract][Full Text] [Related]
8. Preparedness for an anthrax attack. Franz DR Mol Aspects Med; 2009 Dec; 30(6):503-10. PubMed ID: 19619577 [TBL] [Abstract][Full Text] [Related]
9. Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax. Leffel EK; Bourdage JS; Williamson ED; Duchars M; Fuerst TR; Fusco PC Clin Vaccine Immunol; 2012 Aug; 19(8):1158-64. PubMed ID: 22695155 [TBL] [Abstract][Full Text] [Related]
10. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Brookmeyer R; Johnson E; Bollinger R Proc Natl Acad Sci U S A; 2003 Aug; 100(17):10129-32. PubMed ID: 12890865 [TBL] [Abstract][Full Text] [Related]
12. Public response to an anthrax attack: reactions to mass prophylaxis in a scenario involving inhalation anthrax from an unidentified source. SteelFisher G; Blendon R; Ross LJ; Collins BC; Ben-Porath EN; Bekheit MM; Mailhot JR Biosecur Bioterror; 2011 Sep; 9(3):239-50. PubMed ID: 21819225 [TBL] [Abstract][Full Text] [Related]
13. The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques. Grossman TH; Anderson MS; Drabek L; Gooldy M; Heine HS; Henning LN; Lin W; Newman JV; Nevarez R; Siefkas-Patterson K; Radcliff AK; Sutcliffe JA Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784679 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge. Sivko GS; Stark GV; Tordoff KP; Taylor KL; Glaze E; VanRaden M; Schiffer JM; Hewitt JA; Quinn CP; Nuzum EO Vaccine; 2016 Dec; 34(51):6518-6528. PubMed ID: 27155494 [TBL] [Abstract][Full Text] [Related]
15. Estimating the location and spatial extent of a covert anthrax release. Legrand J; Egan JR; Hall IM; Cauchemez S; Leach S; Ferguson NM PLoS Comput Biol; 2009 Jan; 5(1):e1000356. PubMed ID: 19360099 [TBL] [Abstract][Full Text] [Related]
16. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Deziel MR; Heine H; Louie A; Kao M; Byrne WR; Basset J; Miller L; Bush K; Kelly M; Drusano GL Antimicrob Agents Chemother; 2005 Dec; 49(12):5099-106. PubMed ID: 16304178 [TBL] [Abstract][Full Text] [Related]
17. Anthrax postexposure prophylaxis in postal workers, Connecticut, 2001. Williams JL; Noviello SS; Griffith KS; Wurtzel H; Hamborsky J; Perz JF; Williams IT; Hadler JL; Swerdlow DL; Ridzon R Emerg Infect Dis; 2002 Oct; 8(10):1133-7. PubMed ID: 12396928 [TBL] [Abstract][Full Text] [Related]
18. No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001. Baggett HC; Rhodes JC; Fridkin SK; Quinn CP; Hageman JC; Friedman CR; Dykewicz CA; Semenova VA; Romero-Steiner S; Elie CM; Jernigan JA Clin Infect Dis; 2005 Oct; 41(7):991-7. PubMed ID: 16142664 [TBL] [Abstract][Full Text] [Related]
19. Anthrax vaccines: present status and future prospects. Kaur M; Singh S; Bhatnagar R Expert Rev Vaccines; 2013 Aug; 12(8):955-70. PubMed ID: 23984963 [TBL] [Abstract][Full Text] [Related]